Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy

Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy

Background PD1 immune checkpoint blockade (αPD1 ICB) has shown unparalleled success in treating many types of cancer. However, response to treatment does not always lead to tumor rejection. While αPD1 ICB relies on cytotoxic CD8+ T cells, antigen-presenting cells (APCs) at the tumor site are also ne...

Full description

Bibliographic Details
Main Authors: Matheus H W Crommentuijn, Sjoerd T T Schetters, Laura J W Kruijssen, Yvette van Kooyk, Ernesto Rodriguez, Jan Van den Bossche, Joke M M Den Haan
Format: Article
Language:English
Published: BMJ Publishing Group 2020-07-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/2/e000588.full

Internet

https://jitc.bmj.com/content/8/2/e000588.full

Similar Items